ArticleHuman vaccines & immunotherapeutics2023
HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US.
Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Human papillomavirus vaccination at age 9 or 10 years to increase coverage - a narrative review of the literature, United States 2014-2024.Human vaccines & immunotherapeutics · 2025Pooled it
- Prophylactic HPV vaccination in HPV-related gynecologic cancers: European Society of Gynecological Oncology (ESGO) prevention committee opinion.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Guideline
- Trial
- Article
- Electronic Health Record Alerts for Early Human Papillomavirus Vaccination.JAMA network open · 2026Article
- Baseline characteristics of the HOMINY (human papillomavirus, human immunodeficiency virus, and oral microbiota interplay in Nigerian youth) prospective longitudinal cohort.Frontiers in oral health · 2026Article
- Healthcare provider perspectives on HPV vaccinations at ages 9-10 in the United States.Human vaccines & immunotherapeutics · 2025Article
- Parental acceptance of HPV vaccinations at ages 9-10 in the United States.Human vaccines & immunotherapeutics · 2025Article
- "It really is HPV that's pulling us down": Findings from a health plan quality improvement learning collaborative targeting the HEDIS IMA measure.Human vaccines & immunotherapeutics · 2025Article
- Using immunization registry data to explore initiation of HPV vaccination at ages 9 and 10.Human vaccines & immunotherapeutics · 2025Article
- HPV vaccination in community health organizations: what is going right and how can it be replicated?Cancer causes & control : CCC · 2025Observational
- How Immunization Information Systems Inform Age-Based HPV Vaccination Recommendations in the United States: A Mixed-Methods Study.Vaccines · 2025Article
- Human papillomavirus vaccine administration opportunities at well visits in adolescents.BMC public health · 2025Article
- Socioeconomic disparities in HPV vaccine uptake: multivariable analysis of vaccination data from Tianjin (2018-2023).Frontiers in public health · 2025Article
- Contemporary provider perspectives on how to address HPV vaccine hesitancy in the US: A qualitative study.Vaccine: X · 2024Article
- Article
- Article
- Assessing the long-term implications of age 9 initiation of HPV vaccination on series completion by age 13-15 in the US: projections from an age-structured vaccination model.Frontiers in pediatrics · 2024Article
- Evidence supporting the initiation of HPV vaccination starting at age 9: Collection overview.Human vaccines & immunotherapeutics · 2023Article
- Mothers' perceptions and attitudes about HPV vaccination initiation among 9- and 10-year-olds.Human vaccines & immunotherapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The US Advisory Committee on Immunization Practice recommends routine human papillomavirus (HPV) vaccination at 11-12 years of age, but states that vaccination may be initiated as early as 9 years. Our primary goal was to assess whether initiating HPV vaccination at 9-10 years of age, compared to 11-12, was associated with a higher rate of series completion by 13 years of age, and to identify factors associated with series completion by age 13. The study used vaccine claims and other data from the IBM MarketScan Commercial Claims and Encounters (privately insured) and IBM MarketScan Multi-State Medicaid (publicly insured) databases. Participants were 9-12 years of age and initiated HPV vaccination between January 2006 and December 2018 (publicly insured) or February 2019 (privately insured). Among 100,117 privately insured individuals, those initiating the HPV vaccination series at 9-10 years of age had a significantly higher series completion rate by 13 years of age than did those initiating at 11-12 years of age (76.2% versus 48.1%;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.